Andere talen Virax Biolabs Group Limited

Aandelen

VRAX

KYG9495L1251

Vertraagde tijd Nasdaq Andere beurzen 18:59:54 05-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,195 ^USD	+8,64%		+3,02%	-18,15%

11/06	Virax Biolabs Group Limited kondigt wijzigingen in de leiding aan	CI
06/06	Top stijgers premarket	MT

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Virax Biolabs Group Limited Announces Executive Changes	11/06
Top Premarket Gainers	06/06
Virax Biolabs : Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024 - Form 6-K	25/04
Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024	25/04
Virax Biolabs to Participate at ESCMID Global 2024	17/04
Virax Biolabs : to Participate at ESCMID Global 2024 - Form 6-K	16/04
Virax Biolabs : Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency - Form 6-K	15/03
Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2023	12/01
Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients	22/12
Virax Biolabs Group Limited Forges Strategic Research Collaboration with University of Manchester and Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients	21/12
Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation	15/12
Top Premarket Gainers	12/12
Virax Biolabs : Notice of 2023 Annual General Meeting of Shareholders To Be Held on - Form 6-K	08/11
Virax Biolabs : CLAWBACK POLICY - Form 6-K	31-10-23
Virax Biolabs Group Limited announced that it has received $2.15 million in funding	17-10-23
Virax Biolabs Group Limited announced that it expects to receive $2.15 million in funding	12-10-23
Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar	13-09-23
Virax Biolabs : Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar - Form 6-K	12-09-23
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum	04-09-23
Virax Biolabs Group Names Nigel McCracken Operating Chief.	01-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Virax Biolabs Group Limited

Aandelen

VRAX

KYG9495L1251

Andere talen

Filters